Using monoclonal antibodies in the treatment of steroid-sensitive nephrotic syndrome in children

FAYZAKHMATOVA Feruza Ozod kizi, KHAMZAEV Komiljon Amirovich, MAMATKULOV Bahrom Bosimovich

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali · 2026-yil

Annotatsiya

Introduction. Nephrotic syndrome (NS) is one of the most common glomerular diseases in childhood. Although corticosteroids remain the cornerstone of initial therapy, approximately 50% of affected children develop frequently relapsing or steroid-dependent disease. In cases refractory to conventional immunosuppressive agents, rituximab - a chimeric anti-CD20 monoclonal antibody - has emerged as a promising therapeutic option. Aim. To evaluate the efficacy of rituximab in achieving sustained remission in children with steroid-sensitive nephrotic syndrome and to identify clinical predictors of favourable treatment outcomes. Methods. A prospective study enrolled 85 children with primary NS treated at the National Children's Medical Centre between 2021 and 2025. All patients received two rituximab infusions (750 mg/m²) administered 14 days apart; those maintaining remission received repeated infusions every six months (three courses total). Statistical analysis included the Mann–Whitney U test for continuous variables and Fisher's exact test with odds ratio (OR) calculation for categorical data. Results. Sustained remission was achieved in 68 patients (80%); post-treatment relapse occurred in 33 children (38.8%). Statistically significant predictors of remission included older age at disease onset (5.07 vs 3.49 years; p=0.023), older age at the time of rituximab administration (11.57 vs 8.90 years; p=0.013), and low pre-treatment relapse frequency (p=0.010). Continued immunosuppressive therapy after rituximab was associated with lower odds of remission (OR=0.172; 95% CI: 0.053–0.560; p=0.004), most likely reflecting confounding by indication. Gender, biopsy findings, and disease duration prior to treatment were not significant predictors. No serious adverse events were recorded; mild infusion reactions occurred in 7.1% of patients. Conclusion. Rituximab is a highly effective and well-tolerated treatment for steroid-sensitive nephrotic syndrome in children, achieving sustained remission in 80% of patients with a six-monthly re-dosing protocol. Older age at disease onset, older age at first infusion, and low pre-treatment relapse frequency are associated with favourable outcomes. Prospective studies are needed to optimise dosing regimens and re-treatment intervals.

Maqola ma’lumotlari
MualliflarFAYZAKHMATOVA Feruza Ozod kizi, KHAMZAEV Komiljon Amirovich, MAMATKULOV Bahrom Bosimovich
JurnalJournal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali
NashriyotТошкент давлат стоматалогия институти, , «Expert Lawyers» MЧЖ
ISSN2181-9300
Nashr sanasi2026-05-19
Jild11
Son2
TilIngliz
Ilmiy sohaTibbiyot
Indeksga qo‘shilgan2026-08-27

Maqolaning asl sahifasi

Kalit so‘zlar

Нефротический синдром, ритуксимаб, стероид-чувствительный нефротический синдром, деплеция В-лимфоцитов, иммуносупрессия, CD20, Nephrotic syndrome, rituximab, steroid-sensitive nephrotic syndrome, B-cell depletion, immunosuppression, CD20, Nefrotik sindrom, rituksimab, steroidga sezgir nefrotik sindrom, B-limfotsitlar deplesiyasi, immunosupressiya, CD20

Ilmiy soha

Tibbiyot

Iqtibos keltirish

APAFAYZAKHMATOVA Feruza Ozod kizi, KHAMZAEV Komiljon Amirovich, & MAMATKULOV Bahrom Bosimovich (2026). USING MONOCLONAL ANTIBODIES IN THE TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN. Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali, 11(2). https://tadqiqot.uz/index.php/biomedicine/article/view/13857
GOST (OAK)FAYZAKHMATOVA Feruza Ozod kizi, KHAMZAEV Komiljon Amirovich, MAMATKULOV Bahrom Bosimovich USING MONOCLONAL ANTIBODIES IN THE TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN // Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali. – 2026. – T. 11, № 2.
MLAFAYZAKHMATOVA Feruza Ozod kizi, KHAMZAEV Komiljon Amirovich, and MAMATKULOV Bahrom Bosimovich. “USING MONOCLONAL ANTIBODIES IN THE TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN.” Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali, 11(2), 2026. https://tadqiqot.uz/index.php/biomedicine/article/view/13857
ChicagoFAYZAKHMATOVA Feruza Ozod kizi, KHAMZAEV Komiljon Amirovich, and MAMATKULOV Bahrom Bosimovich. “USING MONOCLONAL ANTIBODIES IN THE TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN.” Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali, 11(2) (2026). https://tadqiqot.uz/index.php/biomedicine/article/view/13857
HarvardFAYZAKHMATOVA Feruza Ozod kizi, KHAMZAEV Komiljon Amirovich, and MAMATKULOV Bahrom Bosimovich (2026) ‘USING MONOCLONAL ANTIBODIES IN THE TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN’, Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali, 11(2). https://tadqiqot.uz/index.php/biomedicine/article/view/13857
BibTeX
@article{fayzakhmatovaferuzaozodkizi2026,
  title = {USING MONOCLONAL ANTIBODIES IN THE TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN},
  author = {FAYZAKHMATOVA Feruza Ozod kizi and KHAMZAEV Komiljon Amirovich and MAMATKULOV Bahrom Bosimovich},
  journal = {Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali},
  year = {2026},
  volume = {11},
  number = {2},
  url = {https://tadqiqot.uz/index.php/biomedicine/article/view/13857}
}

Boshqa maqola uchun iqtibos tayyorlash

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali jurnalidan boshqa maqolalar

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali — barcha maqolalar · 2026-yil arxivi

Tibbiyot sohasidagi boshqa maqolalar

Tibbiyot sohasidagi OAK jurnallari